DCTD Programs
FOLLOW DCTDDCTD Staff Present at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
DCTD staff presented research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications 
(October 26-30, 2017; Philadelphia, PA). The European Organisation for Research and Treatment of Cancer (EORTC), NCI, and the American Association for Cancer Research (AACR) co-hosted the meeting, and DCTD’s Director, James H. Doroshow, MD, was an Organizing Committee Co-Chair. The meeting highlighted several presentations on NCI-MATCH and posters on a variety of topics.
| Presentation Type/Time/Location | Authors | Title |
|---|---|---|
| Saturday, October 28 | ||
|
Plenary Session 3: Challenges and Opportunities of Genomic Based Clinical Trials Oral Presentation |
AP Chen | NCI-MATCH: A new paradigm in the era of genomic oncology
|
|
Poster Session: Angiogenesis and Antiangiogenesis Agents A002 |
T Navas, AK Srivastava, K Ferry-Galow, H Makhlouf, R Chuaqui, RJ Kinders, DP Bottaro, AP Chen, RE Parchment, S Kummar, JH Doroshow | Evidence of pazopanib-induced epithelial-mesenchymal (EMT) in human tumors
|
|
Poster Session: Biomarkers A053 |
BA Conley, SR Hamilton, S Li, RJ Gray, DR Patton, PT O’Dwyer, RL Comis, JS Abrams, NS Azad, MJ Overman, JD Schoenfeld, PM Williams, JV Tricoli, E Sharon, H Streicher, LN Harris, AP Chen, KT Flaherty | Prevalence of mismatch repair deficiency (dMMR) in the NCI Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) population
|
|
Poster Session: DNA Repair and Modulation A116 |
LH El Touny, E Harris, C Hose, J Connelly, A Monks, D Newton, L Stockwin, M Hollingshead, R Parchment, JH Doroshow, BA Teicher, A Rapisarda | Temozolomide-resistant MGMT/MSI double-negative cancer cells rely on ATR signaling and homologous recombination for DNA repair and survival
|
|
Poster Session: DNA Repair and Modulation A117 |
LH El Touny, J Connelly, C Hose, A Monks, D Newton, L Stockwin, M Hollingshead, R Parchment, JH Doroshow, BA Teicher, A Rapisarda | Modeling ATM loss of function via CRISPR-Cas9 as a predictive tool for therapeutic responses in cancer cells
|
|
Poster Session: Drug Screening A150 |
DM Evans, SH Michael, L Bowles, RM Delosh, J Laudeman, CC Ogle, R Reinhart, T Silvers, R Parchment, J Doroshow, B Teicher | Complex 3D cultures for combination compound screens reveal new insights
|
|
Poster Session: EGFR/Her2 A161 |
G Kaur, JW Connelly, A Rapisarda, JH Doroshow, BA Teicher | Comparison of EGFR inhibitor response of patient-derived NSCLC lines grown as monolayers, simple spheroids, and mixed cell complex spheroids
|
| Sunday, October 29, 2017 | ||
|
Late-breaking Poster Session: LB-B12-B16 |
5 Posters Involving the Pediatric Preclinical Testing Consortium
|
|
|
Poster Session: Pharmacogenetics, Pharmacogenomics, and Therapeutic Response B079 |
G O’Sullivan Coyne, S Kummar, N Takebe, KT Do, R Meehan, R Piekarz, J Zlott, L Juwara, M Quinn, E Sharon, H Streicher, L Rubinstein, C Levine, JH Doroshow, AP Chen | Single agent AZD 1775, a Wee1 inhibitor, shows activity in BRCA deficient patients
|
|
Poster Session: Pharmacogenetics, Pharmacogenomics, and Therapeutic Response B080 |
L Harris, A Chen, P O’Dwyer, K Flaherty, S Hamilton, L McShane, R Gray, S Li, E Mitchell, D Dragaud, M Williams, J Sklar, AJ Iafrate, D Patton, RF Little, J Zweibel, J Abrams, J Doroshow, B Conley | Update on the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH/EAY131) precision medicine trial
|
|
Poster Session: Pharmacokinetics and Pharmacodynamics B081 |
WG Herrick, CL Kilpatrick, M Hollingshead, JH Doroshow, RE Parchment, AK Srivastava, | Elucidating the pharmacodynamics of PI3K and Ras-Raf signaling through isoform-specific multiplexed quantification of downstream effector phosphorylation
|